FDA OKs Phase 2 Trial of Ampligen Combo as Pre-surgery PC Treatment

FDA OKs Phase 2 Trial of Ampligen Combo as Pre-surgery PC Treatment
The U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase 2 clinical trial testing Hemispherx Biopharma's Ampligen (rintatolimod), in combination with aspirin or aspirin plus Intron A (interferon-alpha 2b), as a treatment for prostate cancer patients before surgery. The randomized clinical trial (NCT03899987) will be carried out at Roswell Park Comprehensive Cancer Center in Buffalo, New York. It plans to include 60 participants. Ampligen — approved in Argentina for severe cases of chronic fatigue syndrome — is an immune modulator that activates specific immune cells that attack cancer cells and increases the number of immune cells that infiltrate the tumor, thus affecting its ability to grow and spread. The trial will combine this therapy with aspirin, which is expected to prevent cancer from coming back after surgery, with or without Intron A. The trial will include a third group of patients who will receive surgery without any treatment beforehand. Intron A is a lab-made version of a human interferon — small proteins naturally produced by the body in response to infections — and is expected to improve patients' response to infections and hinder tumor growth. The trial's main goal is to assess the immune composition of the tumor, including immune cells and signaling molecules. Secondary measures include safety and preliminary efficacy
Subscribe or to access all post and page content.

Tagged , , , , , .

Alejandra has a PhD in Genetics from São Paulo State University (UNESP) and is currently working as a scientific writer, editor, and translator. As a writer for BioNews, she is fulfilling her passion for making scientific data easily available and understandable to the general public. Aside from her work with BioNews, she also works as a language editor for non-English speaking authors and is an author of science books for kids.

Leave a Comment

Your email address will not be published. Required fields are marked *